LifeTimes Online  
Blue Cross Blue Shield
March-April 2012, Vol. XXVII, No. 2
Front Page
Getting enough sleep
Generic OTC drugs
Medicine cabinet 'must-haves'
How to dispose of medicines
Dealing with angina
'Sandwich generation' stress
Watch for eye diseases
Heart-healthy oils and spreads
Walk for exercise
Tips for healthy hair
Risks of raw milk
Coffee and depression
New drug for macular degeneration
FDA approves Juvisync
A 'model' hobby
Add joy to your life
New museum showcases Greek history
'Grannies on Safari'
Medicare Basics
Recent News
About LifeTimes Newsletter
Current Issue
Previous Issues

  facebook twitter youtube
  Learn more

Share |
Health Briefs

Tackling type 2 diabetes and high cholesterol

A new prescription drug combines sitagliptin and simvastatin in a single tablet. Sitagliptin is often prescribed for persons with type 2 diabetes; simvastatin is often prescribed to help control cholesterol levels.

Marketed as Juvisync, the drug was recently approved by the U.S. Food and Drug Administration (FDA). Mary H. Parks, M.D., an FDA director, says it is the first product to combine sitagliptin and simvastatin in one fixed dose.

In an FDA news release, Parks adds that Juvisync tablets are available with varying amounts of sitagliptin and simvastatin to meet patients' individual needs. The most commonly reported side effects include upper respiratory infection, runny or stuffy nose, sore throat, headache, and muscle and stomach pain.

A Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association.

© Copyright 2012. . All Rights Reserved.
Home | Important Information